← Eichor
Study identifier: NCT06392295 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Condition: Prostate Cancer · Prostate Adenocarcinoma · Hormone Sensitive Prostate Cancer  ·  Sponsor: University of Miami

PhasePhase 2
Planned participants34
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin J Rich, MD  ·  305-243-4200  ·  brich@miami.edu

Alan Dal Pra, MD  ·  305-243-4200  ·  alan.dalpra@med.miami.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MiamiMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06392295